University Hospital of TOURS
Welcome,         Profile    Billing    Logout  
 93 Trials 
24 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LABBE, Catherine
NCT05714891: Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Active, not recruiting
2
4
Canada
JDQ443
Canadian Cancer Trials Group, Novartis
NSCLC
08/26
03/28
MULLEMAN, Denis
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, adalimumab, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/25
12/25
CAMUS, Vincent
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
NCT03870776: RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

Active, not recruiting
2
110
Europe
MAP4343, Placebo
Mapreg, Eurofins Optimed
Depression
12/24
03/25
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen Inc.
Peripheral T-cell Lymphoma
05/24
12/25
GISSOT, Valérie
SepSIGN, NCT04261621: Early Identification of SEPsis SIGNs in Emergency Department

Completed
N/A
815
Europe, US, RoW
BioMérieux, Vanderbilt University Medical Center, Centre d'Investigation Clinique - Limoges
Infection, Sepsis
05/22
05/22
BLOUIN, Pascale
CAALL-F01, NCT02716233: A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents

Recruiting
3
1578
Europe
pegaspargase 1250 IU/m2 x 2, ONCASPAR 1250 IU/m2 x 2, pegaspargase 2500 IU/m2 x 1, ONCASPAR 2500 IU/m2 x 1
Assistance Publique - Hôpitaux de Paris, Shire
Acute Lymphoblastic Leukemia
04/26
04/26
Machet, Laurent
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
Maruani, Annabel
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
SESAM, NCT05577754: Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients with Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

Recruiting
2
20
Europe
Alpelisib (BYL719), Matching placebo, Optional lumbar puncture + blood sample
Centre Hospitalier Universitaire Dijon, Novartis Pharmaceuticals
Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
03/27
03/27
Santiago-Ribeiro, Maria-Joao
NCT04265209 / 2019-000247-27: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Recruiting
3
152
Europe
SPECT, PET
Zionexa
Parkinson Disease, Essential Tremor
09/24
12/24
Desmidt, Thomas
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
TAUVERON, Valerie
ACTIODERM, NCT04252690: Physiological Study to Assess Mechanism of Action of MOBIDERM® in Lower-limb Lymphedema Patients

Completed
N/A
9
Europe
MOBIDERM® autofit : auto-adjustable compression stocking
Thuasne, University Hospital, Tours, Delta Consultants
Lymphedema of Leg, Lymphedema Congenital, Lymphedema Primary, Lymphedema, Secondary
06/22
06/22
LYMphoNIGHT, NCT04203069: Auto-Adjustable MOBIDERM® Autofit NIGHT-time Compression Armsleeve in the Upper Limb LYMphedema in Maintenance Phase

Completed
N/A
63
Europe, RoW
Control group : Day-time compression sleeve, Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit
Thuasne, International Clinical Trials Association
Lymphedema of Upper Arm
12/23
09/24
MORINIERE, Sylvain
Eph-L, NCT06014710: Modelling of Pharyngeal Laryngeal Effectiveness

Recruiting
N/A
520
Europe
Swallowing evaluation
University Hospital, Toulouse, National Research Agency, France, Institut de Recherche en Informatique de Toulouse (IRIT), Laboratoire parole et langage, Swallis Medical
Swallowing Disorders
12/24
06/25
Clementy, Nicolas
NCT04735016: DiamondTemp Global Registry

Recruiting
N/A
1000
Europe, RoW
DiamondTemp™ Ablation System
Medtronic Cardiac Rhythm and Heart Failure
Arrhythmia
03/31
03/31
Pierre, Bertrand
ASTRAL-4LV, NCT04463641: Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy

Active, not recruiting
N/A
92
Europe
Implantation of the Axone 4LV Lead
MicroPort CRM
Heart Failure, Cardiac Resynchronization Therapy
06/24
12/27
BIO|STREAM HF, NCT03366545: Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

Recruiting
N/A
3000
Europe, Japan, RoW
Cardiac Resynchronization Therapy (CRT)
Biotronik SE & Co. KG
Heart Failure
03/26
03/26
OEDIPE-CRT-P, NCT05142293: One Day Implantation Program for Heart Failure Patients Implanted With CRT-P

Recruiting
N/A
436
Europe
Ambulatory procedure
Biotronik SE & Co. KG
Heart Failure
03/26
03/26
GILLIBERT-YVERT, Marion
BIOMEDE 2, NCT05476939: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Recruiting
3
409
Europe
Everolimus, VOTUBIA, AFINITOR, ONC201, Radiotherapy
Gustave Roussy, Cancer Campus, Grand Paris, Chimerix, Innovative Therapies For Children with Cancer Consortium, Ministry of Health, France
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
09/28
09/31
Lejeune, Julien
ALLTogether1, NCT04307576 / 2018-001795-38: A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
3
6430
Europe, RoW
Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Besponsa+Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab, Blincyto
Mats Heyman, The Swedish Research Council, The Swedish Childhood Cancer Foundation, Pfizer, Servier, NordForsk, Aamu Pediatric Cancer Foundation, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Clinical Trial Center North (CTC North GmbH & Co. KG), Belgium Health Care Knowledge Centre, Karolinska Institutet, Cancer Research UK, Fundação Rui Osório de Castro, Acreditar - Associação de Pais e Amigos das Crianças com Cancro, Grupo Português De Leucemias Pediátricas, Amgen, Nova Laboratories Limited, Danish Child Cancer Foundation, Danish Cancer Society, The Novo Nordic Foundation, Assistance Publique - Hôpitaux de Paris, Direction Générale de l'Offre de Soins
Leukemia, Acute Lymphoblastic
06/27
06/32
CANCEL, Mathilde
GETUG-AFU 42, NCT06496581: Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Recruiting
3
500
Europe
177Lu-PMSA-617, Pluvicto®, Standard of Care, ADT with an ARSI (i.e. abiraterone + prednisone, or apalutamide, or enzalutamide) ± radiotherapy* or ADT with docetaxel* plus an ARSI (i.e abiraterone + prednisone, or darolutamide,) ± radiotherapy
UNICANCER, Novartis
Prostate Cancer Metastatic
02/33
08/39
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Not yet recruiting
2
198
Europe
Doxorubicin, Trabectedin, Yondelis
UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole
Leiomyosarcoma Uterus
12/29
12/30
Bonnet, Alexandra
APOLLO-EU, NCT05496998: Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - Trial

Recruiting
N/A
400
Europe
Medtronic Intrepid™ TMVR TF System
Medtronic Cardiovascular
Mitral Regurgitation
08/29
12/38

Download Options